Healthcare
Regentis Biomaterials Ltd.(RGNT)
Live Price
Offline$4.75
-22.13% today
Window Change
-36.67%
Window
Dec 4, 2025 โ Jun 17, 2026
- Market Cap
- $10.00M
- Revenue Growth
- 0.0%
- EPS Growth
- 0.0%
- Dividend Yield
- 0.0%
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 133 bars ยท Dec 4, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Regentis Biomaterials Ltd. (RGNT) is a Healthcare stock with a market cap of $10.00M and listed on AMEX. The stock last traded around $4.75 and down 36.7% across the available one-year price window (Dec 4, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS 0.0%, free cash flow 0.0% with operating margin 0.0% and ROIC 0.0%. Stock Foundry combines RGNT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 26, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is 0.0%, while operating margin sits near 0.0%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RGNT
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RGNT Max Drawdown
-83.38%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RGNT and SPY.
Company Overview
Regentis Biomaterials Ltd.
New York Stock Exchange American
Regentis Biomaterials Ltd., a regenerative medicine company, develops tissue repair solutions that restore the health and enhance quality of life of patients. Its lead product candidate is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries and articular knee cartilage. The company focuses on developing orthopedic treatments using its Gelrin platform that is based on degradable hydrogel implants to regenerate damaged or diseased tissue. Regentis Biomaterials Ltd. was incorporated in 2004 and is based in Herzliya, Israel.
- Leadership
- Ehud Geller
- IPO Date
- Sep 11, 2025
- Employees
- 10
- Street Address
- 60 Medinat Hayehudim Street
- Mailing
- Herzliya, 4676652
- Region
- Herzliya, IL
- Reporting Currency
- USD
- Investor Line
- 972 9 960 1917
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- 0.0%
- Free Cash Flow
- 0.0%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 0.0%
- ROIC
- 0.0%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- โ
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.